NEWS | Innovation for Life

SINGAPORE, October 6, 2022 – Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, announced that the company is attending the 2022 Biosimilar Medicines Conference which takes place in Brussels, Belgium, on October 6 and 7.

The Biosimilar Medicines Conference by Medicines for Europe (MfE) aims to facilitate discussion on existing challenges and future opportunities for biosimilar medicine policy and pharmaceutical legislation. The MfE represents the pharmaceutical companies supplying the largest share of medicines across Europe. According to the association, its members currently supply over 67% of all medicines in Europe.

This year’s conference is held in person after three years since COVID-19 pandemic. Speakers and panellists will explore how to turn the Pharmaceutical Strategy aim to ensure better access and affordability into concrete biosimilar medicine policy measures.

At the conference, many former and current members of European Medicines Agency (EMA) will be speakers and address biosimilar medicine policies. Prestige Biopharma plans to actively engage in discussions on regulations and build network, while seeking opportunities for collaboration with major biopharmaceuticals in Europe.

Dr. Susanne Schmidt, Director of Alliance & Portfolio Management in Prestige Biopharma, will participate in the conference. Dr. Schmidt had served as Senior Director of Global/International Business Development at Pfizer and has 25 years of experience in the biopharmaceutical industry, working for multiple leading pharmaceuticals.

Dr. Schmidt commented: “The healthcare systems and policies in the European market vary from country to country. This conference, which brings together pharmaceutical experts from different countries in Europe, provides a good opportunity for in-depth study and understanding on the European market. We also plan to strengthen our presence in the European market by participating in more conferences held in individual European countries and introducing our pipeline portfolio and R&D results.”